Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-05
2000-06-06
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142372, 514255, 514299, 514563, 514592, 514593, 514825, 514885, 435 1, 435 2, 435 3, 4352401, 4352402, 435244, 435243, 435260, 435962, A01N 4734, A61K 31175
Patent
active
060719109
ABSTRACT:
A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.
REFERENCES:
patent: 4466973 (1984-08-01), Rennie
patent: 4626530 (1986-12-01), Schulte
patent: 4748022 (1988-05-01), Busciglio
patent: 5134166 (1992-07-01), Bernstein
patent: 5243922 (1993-09-01), Welsh et al.
patent: 5510339 (1996-04-01), Gleich et al.
patent: 5631267 (1997-05-01), Gleich et al.
"Airways Obstruction--Bronchial Asthma", Merck Manual, 14th Edition, R. Berkow (ed.), Merck Sharp and Dohme Research Laboratories, 622-627, (1982).
"Remington's Pharmaceutical Sciences", 17th Ed., A.R. Gennaro et al. (eds.) Philadelphia College of Pharmacy and Science, 1051-1052, (1985).
Ayars, G.H., et al., "Injurious Effect of the Eosinophil Peroxide-Hydrogen Peroxide-Halide System and Major Basic Protein on Human Nasal Epithelium in vitro", Am. Rev. Resp. Dis., 140, 125-131, (1989).
Barnes, P.J., "The Lancet", 242, (Feb. 1, 1986).
Bascom, R., et al., "Major Basic Protein and Eosinophil-Derived Neurotoxin Concentrations in Nasil-Lavage Fluid After Antigen Challenge: Effect of Systemic Corticosteroids and Relationship to Eosinophil Influx", J. Allergy Clin. Immunol., 84, 338-346, (1989).
Butterfield, J.H., et al., "Chapter 8: Anti-Inflammatory Effect of Glucocorticoids on Eosinophils and Neutrophils", Anti-Inflammatory Steriod Action: Basic and Clinical Aspects., Schleimer et al., editors, Academic Press Inc., 151-198, (1980).
Chen, W.Y., et al., "Effects of Inhaled Lidocaine on Exercise-Induced Asthma", Respiration, 51, 91-97, (1987).
Downes, H., et al., "Lidocaine Aerosols Do Not Prevent Allergic Bronchoconstriction", Anesth. Analg., vol. 60, No. 1, 28-32 (1981).
Dunnill, M.S., "The Pathology of Asthma, with Special Reference to Changes in the Bronchial Mucosa", J. Clin. Path., 13, 27-33, (1960).
Enright, P.L., et al., "Am. Rev. Resp. Disease, 172", 823, (1980).
Filley, W.V., et al., "Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma", The Lancet, 2, 11-16, (1982).
Frigas, E., et al., "Cytotoxic Effects of the Guinea Pig Eosinophil Major Basic Protein on Tracheal Epithelium", Lab. Invest., 42, 35-43, (1980).
Frigas, E., et al., "Elevated Levels of the Eosinophil: Granule Major Basic Protein in the Sputum of Patents with Bronchial Asthma", Mayo Clinic. Proc. 56:345, (1981).
Fujisawa, T., et al., "Regulatory Effects of Cytokines on Eosinophil Degranulation", J. Immunol., 144, 642-646, (1990).
Gross, N.J., et al., "Chapter 34: Anticholinergic Drugs", Allergy, Principles and Practice, vol. 1, E. Middleton Jr. et al., ed., The C.V. Mosby Company, Publisher, 782-808, (1988).
Gundel, R.H., et al., "Repeated Antigen Inhalation Results in a Prolonged Airway Eosinophilia and Airway Hyperresponsiveness in Primates", J. Appl. Physiol., 68, 779, (1990).
Horn, B.R., et al., "Total Eosinophil Counts in the Management of Bronchial Asthma", N. Engl. J. Med., 292, 1152, (1975).
Kita, et al., J. Immunol., 149, 629, (1992).
Krasnowska, M., et al., "A Test of Lidocaine Usage in the Treatment of Bronchial Asthma", Pneum. Pol., 50, 269-273, (1982).
Lamas, A.M., et al., "Glucocorticoids Specifically Decrease Eosinophil Survival", J. Allergy Clin. Immunol. 85, Abstract No. 554, 282, (1990).
Lamas, A.M., et al., "Human Endothelial Cells Prolong Eosinophil Survival", J. Immunol., 142, 3978, (1989).
Mauser, P.J., et al., "The Effect of Anti-Il-5 on Antigen-Induce Airway Hyperreactivity and Pulmonary Eosinophilia in Guinea Pigs", Am. Rev. Respir. Dis., 145, A859, (1992).
Motojima, S., et al., "Toxicity of Eosinophil Cationic Proteins for Guinea Pig Tracheal Epithelium in Vitro", Am. Rev. Resir. Dis., 139, 801, (1989).
Ohnishi, T., et al., "Lidocaine In Bronchoalveolar Lavage Fluid (BALF) Is An Inhibitor of Eosiniphil-Active Cytokines", Clin. Exp. Immunol., 104, 325, (1996).
Rothenberg, M.E., et al., "Human Eosinophil have Prolonged Survival, Enhanced Functional Properties, and Become Hypodense when Exposed to Human Interleukin 3", J. Clin. Invest., 81, 1986, (1988).
Saperov, V.N., "The Treatment of Bronchial Asthma with the Aid of Intra-Arterial Injections of Novocain", Klin. Med., 45, 50-54, (1967).
Schleimer, R.P., et al., "Effects of Glucocorticosteriods on Inflammatory Cells Relevant to Their Therapeutic Applications in Asthma", Am. Rev. Respir., Dis., 141, 559, (1990).
Sedgwick, J.B., et al., "Immediate and Late Airway Response of Allergic Rhinitis Patients to Segmental Antigen Challenge", Am. Rev. Respir. Dis., 144, 1274, (1991).
Sehmi, R., et al., "Interleukin-5 Selectively Enhances the Chemotactics Response of Eosinophils Obtained from Normal but not Eosinophilic Subjects", Blood, 79, 2952, (1992).
Silberstein, D.S., et al., "Enhancement of Human Eosinophil Cytoxicity and Leukotriene Synthesis by Biosynthetic (Recombinant) Granulocyte-Macrophage Colony-Stimulating Factor", J. Immunol., 137, 3290, (1986).
Silberstein, D.S., et al., "Hemopoietins for Eosinophils", Hematol. Oncol. Clin. North Am., 3, 511, (1989).
Tullett, W.M., "Thorax, 37", 737, (1982).
Valerius, T., et al., "Effects of IFN on Human Eosinophils in Comparison with Other Cytokines", J. Immunol, 145, 2950, (1990).
Wallen, N., et al., "Glucocorticoids Inhibit Cytokine-Mediated Eosinophil Survival", J. Immunol., 147, 3940, (1991).
Wasmoen, T.L., et al., "Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein", J. of Biol. Chem., 263, 12559-12563, (1988).
Bankers-Fulbright Jennifer L.
Gleich Gerald J.
Krass Frederick
Mayo Foundation for Medical Education and Research
LandOfFree
Use of agents to treat eosinophil-associated pathologies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of agents to treat eosinophil-associated pathologies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of agents to treat eosinophil-associated pathologies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213767